We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Amitriptyline Major depressive disorders and anxiety Tablets 10, 25, 50, 75 and 100 mg
Amitriptyline Major depressive disorders and anxiety XR tablets 75 mg
Aripiprazole Schizophrenia, bipolar disorder Tablets 5, 10, 15, 20 and 30 mg
Azithromycin Macrolide antibacterial Film-coated tablets 500 mg
Azithromycin Macrolide antibacterial Powder for oral suspension 200 mg/5 ml
Bimatoprost Intraocular pressure Eye drops, solution 0.3 mg/ml (0.4 ml unit dose)
Calcium Dobesilate [S] Non proliferative diabetic retinopathy Hard capsules 500 mg
Carmellose - Artificial tears Dry eye Eye drops, solution (unit dose) 2 mg
Ciprofloxacin otic Otitis Ear drops, solution (unit dose) 1 mg
Clomethiazole [S] Insomnia, restlessness, agitation Soft capsules 192 mg
Clonazepam Epilepsy Oral drops, solution 2.5 mg/ml
Clonazepam Epilepsy Tablets 0.5 mg and 2 mg
Clopidogrel Atherothrombosis Film-coated tablets 75 mg
Desloratadine Allergy Film-coated tablets 5 mg
Dexketoprofen Analgesic Film-coated tablets 12.5 and 25 mg
Duloxetine Major depressive disorders, neuropathic pain, anxiety Gastro resistant hard capsules 30 and 60 mg
Enalapril Hypertension Tablets 5 and 20 mg
Enalapril + HCTZ Hypertension Tablets 20/12.5 mg
Eslicarbazepine Schizophrenia Film-coated tablets 800 mg
Ethosuximide Epilepsy, absence seizures Soft capsules 250 mg
FDF PRODUCT PORTFOLIO

[S] Singular Generics

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.